Bill Text: CT SB00545 | 2017 | General Assembly | Introduced
Bill Title: An Act Concerning A Study Of Requests By Health Care Providers To Override Step Therapy Drug Regimens For Certain Cancer Patients.
Sponsorship: Partisan Bill (Democrat 1)
Status: (Introduced - Dead) 2017-01-26 - Reserved for Subject Matter Public Hearing [SB00545 Detail]
Download: Connecticut-2017-SB00545-Introduced.html
General Assembly |
Proposed Bill No. 545 |
||||
January Session, 2017 |
LCO No. 2990 | ||||
*02990* | |||||
Referred to Committee on INSURANCE AND REAL ESTATE |
|||||
Introduced by: |
|||||
SEN. KENNEDY, 12th Dist. |
|||||
AN ACT CONCERNING A STUDY OF REQUESTS BY HEALTH CARE PROVIDERS TO OVERRIDE STEP THERAPY DRUG REGIMENS FOR CERTAIN CANCER PATIENTS.
Be it enacted by the Senate and House of Representatives in General Assembly convened:
That the Insurance Commissioner shall study and report on (1) the processes that insurance companies, hospital service corporations, medical service corporations, health care centers and other entities that use step therapy for prescription drugs employ in assessing requests made by treating health care providers to override the use of step therapy drug regimens for insureds diagnosed with metastatic cancer, and (2) the response time to such requests.
Statement of Purpose:
To require a study and report on the processes that insurance companies, hospital service corporations, medical service corporations, health care centers and other entities that use step therapy for prescription drugs employ in assessing requests made by treating health care providers to override the use of step therapy drug regimens for insureds diagnosed with metastatic cancer and the response time to such requests.